10 NEWS
Repatha * 1
10 NEWS
22 AUGUST 2025 ausdoc. com. au
Flushes‘ signal perimenopause’
|
Mohana Basu A LANDMARK study on meno- |
|
|
|
as well as vaginal dryness, may be the clearest indicators of onset, |
40-69, using the Stages of Reproductive Aging Workshop + 10 crite- |
were also common but showed less variation across menopausal |
|
pausal transitions suggests that |
independent of menstrual cycle |
ria to classify menopausal stages |
stages. |
|
current staging criteria may be |
changes, they wrote in The Lancet |
and applying the Menopause-Spe- |
The authors said nearly 40 % |
|
outdated and require new defini- |
Diabetes and Endocrinology. |
cific Quality of Life questionnaire |
of perimenopausal women had |
|
tions, particularly in relation to |
“ These findings suggest that |
to assess symptom burden. |
untreated moderate to severe vaso- |
|
perimenopause. |
classic vasomotor symptoms |
They found that moderate to |
motor symptoms. |
|
Led by Monash University’ s Pro- |
should be considered as a diagnos- |
severe hot flushes were nearly five |
“ The earlier-than-currently-rec- |
|
fessor Susan Davis, the authors |
tic criterion for perimenopause or |
times more common in women in |
ognised onset of perimenopause |
|
found that perimenopause might |
postmenopause when menopause |
late perimenopause compared with |
needs further attention to ensure |
|
start earlier than traditionally |
can’ t be distinguished by the bleed- |
premenopausal women. |
highly symptomatic women are not |
Professor Susan Davis. |
accepted and be marked by significant vasomotor symptoms.
Hot flushes and night sweats,
|
ing pattern,” Professor Davis said. The researchers analysed data from more than 5500 women aged |
Vaginal dryness was 2.5 times more prevalent, they found.
Poor memory and low mood
|
dismissed,” they said.
Lancet Diabetes Endocrinol 2025; 25 Jul.
|
|
|
|
|
Surgeons die before other docs |
Repatha * 1
Proven to reduce plaque † 2 and to prevent CV events ‡ 3 vs placebo 1-4
* Repatha is indicated for the prevention of CV events( MI, stroke and coronary revascularisation) in adults with established CV disease in combination with an optimally dosed statin and / or other lipid-lowering therapies, as an adjunct to diet and exercise. 1
†
Adding Repatha to statins resulted in a 0.95 % reduction in percent atheroma volume( percentage of outer vessel wall volume occupied by plaque) at week 78( p < 0.001 vs baseline and vs placebo [+ 0.05 %]). 2
‡
Relative risk of the primary composite end point( CV death, MI, stroke, hospitalisation for UA, or coronary revascularisation) significantly reduced by 15 % over 2.2 years follow-up with REPATHA plus optimised statin ± ezetimibe( HR 0.85 [ 0.79-0.92 ]; p < 0.001) – with consistent results across age, sex, and type of ASCVD. 3
PBS Information: Authority required( STREAMLINED). Non-familial and familial hypercholesterolaemia. Criteria apply. Refer to PBS Schedule for full authority information.
Refer to full Product Information before prescribing; available from Amgen Australia Pty Ltd, Ph: 1800 803 638 or by scanning the QR code: For more information on Repatha ® or to report an adverse event or product complaint involving Repatha ®, please contact Amgen Medical Information on 1800 803 638 or visit www. amgenmedinfo. com. au.
Precautions: Hypersensitivity reactions. Concomitant lipid-lowering therapies – check all relevant prescribing information. Immunogenic potential. Pregnancy Category: B1. Caution – breastfeeding. Adverse Reactions: Common – nasopharyngitis, upper respiratory tract infection, influenza, back pain, arthralgia, nausea, rash, and injection site reactions( including injection site pain, erythema, bruising, swelling or haemorrhage). 1
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction; PBS, Pharmaceutical Benefits Scheme; UA, unstable angina.
References: 1. Repatha( evolocumab) Product Information. 2. Nicholls SJ, et al. JAMA 2016; 316:2373 – 2384. 3. Sabatine MS, et al. N Engl J Med. 2017; 376( 18): 1713 – 1722. 4. Gencer B, et al. JAMA Cardiol. 2020; 5( 8): 952 – 957.
Amgen Australia Pty Ltd. ABN 31 051 057 428, Sydney NSW 2000. © 2025 Amgen Inc. All rights reserved. AUS-145-0725-80014. AMGREP2615. Date of preparation: July 2025.
Carmel Sparke DEATH certificate data have revealed a higher mortality rate for surgeons than other doctors, especially from car crashes, assaults and hypertension.
Researchers from Harvard Medical School in Boston, Massachusetts, found that the 2023 ageand sex-adjusted mortality rate for surgeons was 355 per 100,000 versus 228 for other doctors.
“ Given the demands of surgical practice— including long work hours, high-pressure environments, workplace violence and occupational exposures( eg, radiation)— surgeons might be particularly vulnerable to health risks,” they wrote in JAMA Surgery.
They compared the 224 surgeon deaths with three groups: other doctors; other educated, high-income professionals, such as lawyers; and all other workers.
They found that car crashes were the fourth most likely cause of death for surgeons but ranked ninth for the others.
Deaths from hypertension, assault and cancer also ranked higher for surgeons than for the other groups.
“ Higher mortality rates among surgeons might reflect differences related to work environment, professional demands and lifestyle. Our results indicate that several causes of death( eg, motor vehicle collisions) disproportionately affect surgeons, aligning with evidence that hazardous driving events associated with extended work hours are especially pronounced among surgeons,” the researchers said.
The data covered all 1.08 million US deaths of 25-74-year-olds in 2023.
JAMA Surg 2025; 30 Jul.